Context Therapeutics' $100M placement; Blueprint raises guidance for rare disease drug
02 May 2024
Drug Approval
Plus, news about Novocure and Corvus:
Context Therapeutics’ $100M PIPE:
Nextech
led
the private placement, and other investors like Ally Bridge Group took part. The solid tumor biotech also
said
the FDA cleared human testing of the company’s bispecific antibody CTIM-76.
— Kyle LaHucik
Blueprint Medicines raises sales guidance, stock jumps 15%:
The company’s rare disease drug Ayvakit
generated
$92.5 million in revenue in the first quarter of 2024, and Blueprint is now raising its guidance on annual sales of the drug by $20 million to $410 million. The treatment’s label was
expanded
last year to a broader patient population that includes those with indolent systemic mastocytosis, a rare disease in which too many of a kind of white blood cell build up in the body.
— Lei Lei Wu
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.